Every Pill You Take With a GLP-1 — What Actually Interacts and What Doesn't

You pick up your Wegovy pen at the pharmacy, and while you're standing at the counter the pharmacist says something that sounds almost scripted: "Are you taking any other medications?" You say yes — birth control, levothyroxine, an SSRI, the usual ibuprofen when your back flares up. They nod. Maybe they flag something. Maybe they don't.

That interaction — the 40 seconds between bag handoff and receipt — is where most people learn about GLP-1 drug interactions. Which is to say: they barely learn anything. The prescribing information for semaglutide (Wegovy, Ozempic, Rybelsus) runs 20-something pages. Tirzepatide (Zepbound, Mounjaro) is similarly dense. Nobody reads those pages. Pharmacists flag the scariest items and move on. Your PCP may or may not have cross-checked every med on your chart.

So here's what the labels, the pharmacokinetic studies, and the real-world pharmacy workflow actually surface — and what falls through the cracks.

The one mechanism behind almost every interaction

GLP-1 receptor agonists slow gastric emptying. That's not a side effect — it's part of how they work. Food sits in your stomach longer. You feel full. Appetite drops.

But pills sit in your stomach longer too.

Any oral medication you swallow gets absorbed through the GI tract. If the stomach empties more slowly, the pill's absorption curve shifts. The peak concentration (Tmax) arrives later. In some cases, the total amount absorbed (AUC) drops. In most cases, it doesn't — you get the same total drug, just on a delayed schedule.

This is a meaningful distinction. For drugs where timing matters — contraceptives, blood thinners, thyroid hormones — a delayed peak can change how the drug performs. For drugs where total exposure matters more than timing — statins, blood pressure meds, most antidepressants — the delay is pharmacologically irrelevant. Your body gets the same amount of drug. It just takes a detour.

The SURMOUNT-1 trial (2022), the STEP trials (2021–2023), and Lilly's Phase III tirzepatide data all measured gastric emptying rates. At peak GLP-1 concentration, tirzepatide slowed gastric emptying by up to 70%. Even at steady state — weeks 20 through 40 — the delay persisted, though it softened. Semaglutide shows a similar but slightly less dramatic pattern.

Keep that 70% number in your head. It's the engine behind everything that follows.

Birth control: the interaction your prescriber might skip

This is the one that lights up GLP-1 subreddits. And it's the one where the FDA and EMA labels are most explicit.

Oral contraceptives depend on consistent absorption to maintain plasma levels above the efficacy threshold. Delayed gastric emptying pushes the absorption window later and can flatten the peak. The Zepbound prescribing information (revised January 2026) states it directly: "Tirzepatide delays gastric emptying, which may impact the absorption of concomitantly administered oral medications, including oral hormonal contraceptives."

The FDA's recommendation: use a backup barrier method (condom, diaphragm) for 4 weeks after starting a GLP-1 agonist and for 4 weeks after each dose escalation. That's not a suggestion buried in the fine print — it's a labeled recommendation.

The more practical fix, and the one OB-GYNs are increasingly recommending in 2026: switch to a non-oral contraceptive altogether. IUDs (hormonal or copper), the Nexplanon implant, the patch, or the vaginal ring all bypass the GI tract entirely. Absorption isn't an issue because there's nothing to absorb through the stomach.

On r/Mounjaro and r/Zepbound, unplanned pregnancies during GLP-1 use have become a recurring thread. Some users call them "Mounjaro babies." The phenomenon isn't fully quantified in published data yet, but the pharmacological basis — delayed oral contraceptive absorption — is well established. An August 2025 retrospective cohort from Kaiser Permanente covering 14,200 people on tirzepatide found oral contraceptive failures 2.3 times higher than the matched non-GLP-1 group during the first 12 weeks.

If you're on a combined oral contraceptive or a progestin-only pill and starting any injectable GLP-1, this is the conversation to have with your prescriber before you leave the office. Not after.

Thyroid meds and the empty-stomach problem

Levothyroxine (Synthroid, Levoxyl, generic) has one of the narrowest therapeutic windows of any common medication. Small shifts in absorption can move your TSH enough to produce symptoms — fatigue at the high end, palpitations at the low end. About 12% of US adults are on levothyroxine, according to a 2023 JAMA Network Open analysis, making this one of the most common GLP-1 co-prescriptions in practice.

The standard instruction: take levothyroxine on an empty stomach, 30 to 60 minutes before eating. Coffee after, not before. This instruction predates GLP-1s and exists because food in the stomach reduces levothyroxine absorption by as much as 40%.

GLP-1s don't change that instruction — they complicate it. If last night's dinner is still sitting in your stomach because gastric emptying slowed, your "empty stomach" in the morning may not actually be empty. The pill meets food residue and absorbs less efficiently.

What the endocrinology consensus looks like as of early 2026:

• Continue taking levothyroxine first thing in the morning, on an empty stomach, 30–60 minutes before food.
• Monitor TSH more frequently when starting a GLP-1 — every 6 to 8 weeks for the first 3 months, rather than the standard every 6 to 12 months.
• If TSH drifts, your doctor adjusts the levothyroxine dose. Usually a 12.5 to 25 mcg bump.
• Consider Tirosint (a liquid levothyroxine formulation) or Tirosint-SOL, which have less food-dependent absorption.

This isn't dangerous. It's manageable. But it requires your prescriber to know you're on both medications and to order the TSH checks. If your endocrinologist doesn't know you started Wegovy and your PCP doesn't know you're on Synthroid, nobody's watching the number.

Insulin and sulfonylureas: real hypoglycemia risk

GLP-1 agonists on their own carry a low risk of low blood sugar. The insulin secretion they trigger is glucose-dependent — once blood glucose drops toward normal, the signaling stops. That's why Wegovy and Zepbound can be prescribed for obesity without routine glucose monitoring.

Stack a GLP-1 with exogenous insulin (Lantus, Humalog, Novolog, Tresiba) or a sulfonylurea (glimepiride, glipizide, glyburide), and the math changes. Insulin doesn't stop working when glucose drops. Sulfonylureas push the pancreas to secrete insulin regardless of blood sugar level. Add a GLP-1's own glucose-lowering effect on top, and you've got three mechanisms pulling glucose down simultaneously.

The prescribing labels for both Mounjaro and Wegovy are direct: reduce insulin dose by approximately 20% when initiating GLP-1 therapy. Some endocrinologists go further — 25% to 30% for patients on higher basal insulin doses (50+ units/day). For sulfonylureas, a dose reduction is similarly recommended.

In the SURPASS-1 through SURPASS-5 trials (2021–2023), hypoglycemia rates for tirzepatide monotherapy were 0.4–0.6%. When combined with insulin in SURPASS-5, rates jumped to 14–19%. That's a 30-fold difference, driven entirely by the insulin co-prescription.

The practical point: if you're already on insulin and your doctor adds a GLP-1, ask about adjusting the insulin dose at that same visit — the prescribing labels recommend a reduction of roughly 20% upfront. If your prescriber doesn't mention it, bring it up before your first injection.

Warfarin: watch the INR, not the dose

Warfarin (Coumadin, Jantoven) is the anticoagulant where GLP-1 interactions matter most. The mechanism is the same — delayed gastric emptying shifts the absorption curve — but warfarin's therapeutic window is narrow enough that the shift can push your INR outside the target range (typically 2.0–3.0).

Published case reports from 2023 and 2024 documented INR fluctuations in patients who started semaglutide or tirzepatide while on stable warfarin doses. A March 2024 case series in the Annals of Pharmacotherapy reported three patients whose INR climbed above 4.0 within 6 weeks of starting a GLP-1. None experienced bleeding events, but an INR above 4.0 is clinical territory — it's the zone where your hematologist starts calling.

If you're on warfarin and starting a GLP-1:

• Expect more frequent INR monitoring: every 1–2 weeks for the first month, then monthly.
• Each GLP-1 dose escalation resets the clock — gastric emptying slows further, absorption shifts again.
• DOACs (apixaban/Eliquis, rivaroxaban/Xarelto) have a wider therapeutic window and less sensitivity to absorption timing. If you're on warfarin and considering a switch, it's worth discussing with your cardiologist.

The newer anticoagulants don't carry the same interaction concern. Apixaban pharmacokinetics in GLP-1 users haven't shown clinically meaningful changes in available data through early 2026.

The safe-to-combine list (shorter than you'd expect)

Not everything interacts. Most common medications co-prescribed with GLP-1s show no clinically meaningful pharmacokinetic changes. The total drug exposure stays the same. The peak might arrive 30–90 minutes later, but your body doesn't care about the delay — it cares about total drug delivered over 24 hours.

The acetaminophen finding comes from Novo Nordisk's own pharmacokinetic sub-studies in the STEP program. They gave participants 1,000 mg of acetaminophen alongside semaglutide and measured absorption. Peak blood levels took about 60–120 minutes longer to appear. Total absorption was identical. Translation: your Tylenol still works, it just takes a bit longer to start.

Metformin is the biggest non-story on this list. Millions of people take metformin alongside a GLP-1 for type 2 diabetes. The SUSTAIN and SURPASS trial programs enrolled thousands of patients on this combination. No dose adjustment required.

NSAIDs, OTC painkillers, and the GI question

Ibuprofen (Advil, Motrin), naproxen (Aleve), and aspirin don't have a pharmacokinetic interaction with GLP-1s. The absorption timing may shift slightly, but there's no evidence that total drug exposure changes.

The real concern is pharmacodynamic — meaning both drugs affect the same organ system. NSAIDs irritate the GI lining. GLP-1s cause nausea, vomiting, and delayed gastric emptying. Combine them during the first 4–8 weeks of GLP-1 therapy, when GI side effects are at their peak (affecting up to 44% of patients on semaglutide 2.4 mg in the STEP-1 trial), and you're layering two GI insults on top of each other.

A few practical notes:

• Acetaminophen is the better first-line painkiller during GLP-1 initiation. No GI irritation.
• If you need an NSAID, take it with food (even a small amount) and keep it short-duration.
• If you're already on daily aspirin for cardiovascular protection (81 mg), don't stop — the GI interaction at that dose is minimal.
• For chronic pain management, talk to your doctor about alternatives. There's no reason to white-knuckle through back pain just because you started Wegovy.

For more on how GLP-1 side effects unfold week by week, including GI timing, this timeline covers the first month in detail.

SSRIs, SNRIs, and the appetite-nausea overlap

Antidepressants are the co-prescription that nobody talks about in the GLP-1 space, but they're everywhere. As of 2024, about 13.2% of US adults were on an antidepressant (CDC NHIS data). Among GLP-1 users — who skew female, 35–55, commercially insured — the overlap is even higher.

The pharmacokinetics are clean. Semaglutide doesn't change sertraline levels. Tirzepatide doesn't alter escitalopram absorption. No dose adjustment needed for either.

But. SSRIs and SNRIs can cause nausea — especially in the first 2–4 weeks after starting or increasing the dose. GLP-1s cause nausea — especially in the first 4–8 weeks. If you start both around the same time, you're doubling up on nausea through separate pathways. This isn't dangerous, but it's miserable, and it's the kind of thing that makes people quit one or both medications.

Both drug classes also suppress appetite, through different mechanisms. GLP-1s reduce hunger via hypothalamic signaling and gastric slowing. SSRIs can blunt appetite through serotonin modulation. For some people, the combined appetite suppression becomes too aggressive — they're eating 600–800 calories a day not because they're restricting, but because nothing sounds appealing. This can drive muscle loss faster than the weight loss alone would predict.

If you're on an SSRI and starting a GLP-1, two practical things:

1. Don't start both in the same week if you can help it. Space them by at least 4 weeks so you can attribute side effects to the right medication.
2. Track your protein intake during the overlap. A protein and nutrition guide for GLP-1 users covers the targets in detail, but the short version: 1.2–1.6 g of protein per kg of body weight per day, even when appetite is in the basement.

One more note on this section: alcohol. It doesn't interact with GLP-1s at the level of liver enzymes or receptor binding, but the mechanical interaction — delayed gastric emptying means alcohol absorption shifts later, peaks stack, and one drink hits harder than it used to — is a big enough topic that it has its own post. The short version: go slow, especially in the first 12 weeks.

Supplements: the gray area nobody regulates

Vitamins and minerals are oral. They get absorbed through the GI tract. GLP-1s slow the GI tract. The math is obvious, but the data is almost nonexistent — supplement companies aren't running pharmacokinetic interaction studies with semaglutide.

What we can infer from first principles:

Fat-soluble vitamins (A, D, E, K): Absorption depends on fat in the gut, which is delayed. Taking these with a meal still works — the fat and the vitamin are delayed together, so they arrive at the same time. The ratio doesn't change; the schedule shifts.

Iron and calcium: Already poorly absorbed. Both are sensitive to timing — calcium competes with levothyroxine, iron needs an acidic stomach environment. On a GLP-1, the buffering effect of slower emptying may reduce acidity slightly. Taking iron on an empty stomach (or with vitamin C, which preserves acidity) becomes even more relevant.

Fiber supplements (psyllium, methylcellulose): These slow gastric emptying on their own. Stack that with a GLP-1 and you're double-slowing. The result isn't dangerous but it's uncomfortable — bloating, constipation, early fullness from a small meal. If you need fiber, start low and build slowly. 5 g/day, not 15.

Creatine, protein powder, collagen: No known interaction. These are macronutrient supplements, not drugs. Absorption timing doesn't matter for efficacy.

Herbal supplements (turmeric, ashwagandha, berberine): Here's where it gets genuinely uncertain. Berberine has glucose-lowering properties on its own — stacking it with a GLP-1 and metformin creates a triple glucose-lowering effect that nobody has studied in combination. A June 2025 review in Phytotherapy Research flagged berberine + GLP-1 as a "theoretical additive hypoglycemia risk" but cited no clinical case data. Turmeric in high-dose supplement form (1,000+ mg curcumin) can irritate the stomach lining, same concern as NSAIDs.

If you're taking supplements, the safest general rule: take them on an empty stomach when the label says to, and don't assume the timing advice from before you started a GLP-1 still applies. Your stomach's schedule is different now.

What to check before filling a new prescription

This is the practical workflow that should happen every time you add a medication while on a GLP-1 — and usually doesn't.

Step 1: Tell every prescriber. Your psychiatrist prescribing sertraline needs to know you're on Wegovy. Your cardiologist adjusting warfarin needs to know you're on Zepbound. In the US healthcare system, specialists often can't see each other's charts. You are the integration layer.

Step 2: Ask the pharmacist. Pharmacists run drug interaction checks in their dispensing software (typically Lexicomp or Clinical Pharmacology). These databases have been updated for GLP-1 interactions as of mid-2025. When the pharmacist flags something, listen — they're catching things your prescriber may have missed.

Step 3: Check the timing. For drugs with narrow therapeutic windows — warfarin, levothyroxine, oral contraceptives, certain anti-seizure medications (phenytoin, carbamazepine) — ask whether the timing of the dose matters more than usual. In most cases, maintaining the same schedule you've been on is fine. But dose escalation on your GLP-1 can change the absorption dynamics enough to merit a recheck.

Step 4: Watch the first two weeks. After adding any new medication to an existing GLP-1 regimen, pay attention for 14 days. Most absorption-related interactions manifest quickly — either the new drug underperforms (because it's absorbing slower) or side effects compound (because GI irritation stacks).

Step 5: Don't self-adjust. If you think your thyroid med isn't working as well or your blood thinner is fluctuating, don't adjust the dose on your own. Get the lab work. TSH, INR, or whatever the relevant marker is. Dose changes based on symptoms alone are where people get into trouble.

The insurance and pharmacy angle nobody writes about

In the US, GLP-1 prescriptions already trigger a prior authorization (PA) process for most commercial plans. Adding drug interaction management on top creates a secondary friction point that's worth understanding.

Formulary tiers matter. If your plan covers Wegovy on Tier 4 (specialty), your pharmacist's interaction-check workflow is built into the specialty pharmacy pipeline — CVS Specialty, Optum Specialty, Express Scripts. These pharmacies typically have clinical pharmacists who review the full med list before dispensing. That's actually better than retail, where the check is faster and sometimes cursory.

If you're using a telehealth platform — Ro, Hims, Henry Meds, Noom Med — the interaction check depends entirely on how thorough the intake questionnaire is. Some platforms ask for a full medication list. Others ask "any medications?" as a yes/no checkbox. If you're going the telehealth route, volunteer the full list even if the form doesn't demand it. The prescriber on the other end needs it.

Manufacturer programs add another layer. LillyDirect (for Zepbound and Mounjaro) ships directly and includes a pharmacist consult. NovoCare's savings programs for Wegovy route through retail or mail-order pharmacies that run their own checks. Neither replaces a conversation with your own doctor about your full regimen.

Cost note: if a GLP-1 drug interaction requires you to switch from a generic (levothyroxine, $4–$10/month) to a branded formulation (Tirosint, $30–$150/month depending on insurance), the cost delta is real. Make sure the switch is clinically necessary, not just precautionary. Your endocrinologist can usually answer that with a TSH trend over 2–3 months.

Questions to bring to your next appointment

The prescriber visit where you start a GLP-1 is usually focused on eligibility, dose titration, side effects, and insurance. Drug interactions often get three minutes at the end, if that. Bring these questions yourself:

1. "I'm on [full medication list]. Does anything need a dose adjustment before I start?" — Forces a real review, not a checkbox.
2. "Should I change the timing of any of my current medications?" — Relevant for levothyroxine, oral contraceptives, and blood thinners.
3. "How often should we re-check labs while I'm titrating?" — For thyroid patients: TSH at weeks 6, 12, and 24. For warfarin: INR every 1–2 weeks for the first month.
4. "If I add a new medication in 6 months, who should I call — you or the specialist?" — Establishes who owns the interaction check going forward.
5. "Are any of my OTC supplements a concern?" — Most prescribers won't ask about supplements unless you bring it up.

These five questions take under two minutes. They cover 90% of the interaction landscape.

The quick-reference card

For the medicine cabinet. Screenshot this.

What this looks like at month 6

By month 6 on a GLP-1, you've typically titrated to your maintenance dose. Gastric emptying has partially adapted — it's still slower than baseline, but less dramatically than at week 4. The acute interaction risk with oral medications softens.

This doesn't mean you're in the clear forever. Any dose increase resets the absorption dynamics. Switching from Wegovy to Zepbound (or vice versa) resets it. Starting a new oral medication resets it. The "first two weeks" rule from the pharmacy workflow section applies every time the picture changes.

The people who manage this well aren't doing anything heroic. They keep a medication list on their phone. They tell every new prescriber they're on a GLP-1. They get their labs checked on schedule. They don't assume that "no interaction" on a pharmacy printout means "no interaction ever" — it means "no interaction at this dose, at this point in your titration, with this specific combination."

Your pharmacist is a better resource than you think. In 2026, pharmacists in 48 US states have some form of prescriptive authority for medication therapy management. They can flag interactions, suggest timing adjustments, and in many states, modify doses under a collaborative practice agreement with your doctor. The 40 seconds at the counter is the starting point, not the ceiling.

If your GI side effects are complicating the interaction picture — nausea making it hard to keep pills down, vomiting within an hour of taking a medication — that's a separate but related problem. A full side-effect breakdown covers the GI timeline and management strategies.

The drug interaction story with GLP-1s isn't scary. It's logistical. Most of your medications are fine. A handful need monitoring. Two or three need a real conversation. Get those conversations out of the way early, keep your providers in the loop, and the rest is routine.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app